Marshall Wace LLP Acquires 694,243 Shares of Genmab A/S (NASDAQ:GMAB)

Marshall Wace LLP increased its holdings in shares of Genmab A/S (NASDAQ:GMAB) by 162.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,122,296 shares of the company’s stock after purchasing an additional 694,243 shares during the period. Marshall Wace LLP owned approximately 0.17% of Genmab A/S worth $23,422,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. EverSource Wealth Advisors LLC lifted its stake in Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after buying an additional 939 shares in the last quarter. Lindbrook Capital LLC boosted its stake in Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after purchasing an additional 950 shares during the period. GAMMA Investing LLC boosted its stake in Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after purchasing an additional 1,051 shares during the period. Barclays PLC increased its holdings in Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company’s stock worth $52,000 after purchasing an additional 2,285 shares in the last quarter. Finally, Cromwell Holdings LLC raised its stake in shares of Genmab A/S by 656.8% in the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after purchasing an additional 2,496 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Stock Up 2.5 %

Shares of NASDAQ GMAB opened at $20.04 on Friday. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $30.41. The company has a market cap of $13.26 billion, a PE ratio of 11.52, a price-to-earnings-growth ratio of 2.65 and a beta of 1.07. The business’s 50 day moving average price is $20.54 and its two-hundred day moving average price is $21.15.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, research analysts anticipate that Genmab A/S will post 1.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. BNP Paribas upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. William Blair raised Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. Sanford C. Bernstein lowered shares of Genmab A/S from a “market perform” rating to an “underperform” rating in a research report on Tuesday, April 1st. Truist Financial decreased their target price on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Tuesday, March 11th. Finally, HC Wainwright reissued a “buy” rating and set a $37.00 price target (down from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Genmab A/S presently has an average rating of “Moderate Buy” and a consensus target price of $39.17.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.